Our portfolio includes companies on the cutting edge of innovation with solutions that improve clinical outcomes and have a true financial impact on the healthcare system.
I am a technology guy and a first time CEO. Triventures helped me fill in the blanks, think through ideas and see the big picture.
We couldn’t have turned to a better VC. Their interventional cardiology know-how and industry relationships are off the charts.
It was great to have Triventures as our lead investor. They helped us put together a syndication in which each partner added unique value.
The key added value you want from your investors is for them to become a true partner. You want them to work with you at your side, and together make your company a success. Not many VCs do that… Triventures certainly does.
Triventures believed in us when we were just an idea. Now we have the first image-guided robotic positioning system in the world helping laparoscopic surgeons deliver better care.
Triventures offers more than just financial support. I truly believe we wouldn’t be where we are today, and where we are headed without their advice and relationships.
It is comforting to know that I can call on them at any time of the day on any issue. There is a new challenge every day and they are like the seasoned specialist who is always on call, ready to give a helping hand.
Any medtech venture would be wise to partner with them. They can help you at every stage in the life of a healthcare start up, from crafting IP all the way to executing a sound bizdev strategy.
6over6 is developing a suite of smartphone optometry tools. With its application, anyone anywhere can obtain a complete prescription, pupillary distance (PD), and astigmatism from any smartphone.
Apica and its spinout ApK developed a suite of implant devices designed to improve transapical surgical access and left ventricular assist device implantation. The companies were acquired by Thoratec in July 2014.
Cathworks is developing an image-based approach for assessing FFR (functional flow reserve) in the cath lab using data from standard angiograms.
Eyeyon has developed a therapeutic contact lens platform for chronic corneal edema and other corneal-related disorders and post-operative procedures. Eyeyon is also developing a synthetic fluid barrier that has the potential to displace a difficult cadaver based corneal endothelial transplantation procedure, with a simple, easy to implant off the shelf synthetic product.
Vi is developing ‘Hearable’ headsets with embedded sensors to assess physiological parameters in real-time and artificial intelligence algorithms that learn user preferences and act as a virtual trainer.
V-Wave is developing a minimally invasive device for heart failure. The device regulates left atrial pressure (LAP) by shunting excess blood volume away from the left ventricle – the heart’s main pumping chamber.